

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Ixazomib with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

It was noted during the scoping process that multiple myeloma mostly affects older people and is more common in people of African and Caribbean family origin. Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal. No evidence was presented that suggested the effectiveness or safety of ixazomib citrate was different in people of African and Caribbean family origin compared with other groups.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No equalities issues were raised in the submissions, expert statements or academic report.
--

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No further issues were identified.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Not applicable.

Approved by Associate Director (name): Helen Knight

Date: 20/04/2017

Appraisal consultation document 2

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No additional potential equality issues were raised during consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Not applicable

Approved by Associate Director (name): Helen Knight

Date: 29/08/2017

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No additional potential equality issues were raised during consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Not applicable.

Approved by Associate Director (name): Helen Knight

Date: 16/11/2017